Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, artemether/lumefantrine (Riamet®) cannot be endorsed for use within NHS Wales for the treatment of acute uncomplicated Plasmodium falciparum malaria in infants and children weighing 5 kg to less than 35 kg. |
||
|
||
Medicine details |
||
| Medicine name | artemether/lumefantrine (Riamet®) | |
| Formulation | 20 mg/120 mg dispersible tablet | |
| Reference number | 1757 | |
| Indication | For the treatment of acute uncomplicated Plasmodium falciparum malaria in infants and children weighing 5 kg to less than 35 kg. |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 13/08/2012 | |